Small molecules to lead Leo Pharma to greatness

In 2030, Leo Pharma wants to be the world’s leading firm within medical dermatology, and the road there is firmly anchored in small molecules, which is what the company’s scientists do best. Big molecules – which will continue to play a role – will be sourced externally.
Jörg Möller joined Leo Pharma as head of global research and development a year ago, and is now leading an extensive restructuring of the company's R&D division | Photo: MAGNUS MØLLER
Jörg Möller joined Leo Pharma as head of global research and development a year ago, and is now leading an extensive restructuring of the company's R&D division | Photo: MAGNUS MØLLER
by ULRICH QUISTGAARD, translated by daniel pedersen

Leo Pharma has no doubts about where the road ahead is leading it. By the end of the decade, the company aims to be one of the absolute biggest international organizations within medical dermatology, and is currently going through sweeping changes to get there.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading